Search
Menu
Home
HTB
2006
February
09
HTB
9 February 2006
Contents
Antiretrovirals
SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm
TMC114 (darunavir) new drug applications submitted to US and European regulatory agencies
Treatment access
Missing the target: a report on HIV/AIDS treatment access from the frontlines
New Clinton agreements to lower prices of HIV/AIDS rapid tests and second-line drugs in 50 countries
WHO adds seven antiretrovirals to list of prequalified HIV drugs
Ranbaxy launches two new ARVs in India
FDA tentative approvals: generic oral solutions of nevirapine and d4T
Amendment to WTO TRIPS agreement makes access to affordable medicines even more bleak: MSF expresses concern that patients the world-over will have to pay the price
WTO uses AIDS patients to cover up development round failure